DOCSLIB.ORG

SUPPLEMENTAL INFORMATIONS 2 Supplemental Figures with Legends 3

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
SUPPLEMENTAL INFORMATIONS 2 Supplemental Figures with Legends 3 Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 1 1 SUPPLEMENTAL INFORMATIONS 2 Supplemental Figures with legends 3 A WT young B WT aged ** 6 * 6 4 4 ns ns ns fold LT-HSC ns 2 fold LT-HSC 2 ns ns ns ns ns ns 0 0 MPP CMP GMP MEP liver MPP CMP GMP MEP liver LT-HSC ST-HSC LT-HSC ST-HSC C WT young D *** ns ns 1.5 1.0 ns ns 1.0 ** 0.5 fold HSC 0.5 fold of young 0.0 0.0 Young Aged Old HSC MPP CMP GMP MEP Figure S1. Pon2 mRNA expression in different bone marrow cells of WT mice A and B: LT-, ST-HSCs, MPPs, CMPs, GMPs, MEPs and liver cells were obtained from young (2-3 months) and aged (>9 months) WT mice. Pon2-, Gapdh- and Actb mRNA expression was analyzed by qRT-PCR. Pon2 mRNA expression was normalized to Gapdh and Actb-mRNA expression. The relative Pon2 mRNA expression in LT-HSCs from young or aged WT mice was set to 1. Shown are the mean ± SEM of n=3-6 experiments using 2- 6 mice per group (**p < 0.01, *p < 0.05, ns not significant vs. LS-HSC cells; 1-way Anova with Dunnett's multiple comparisons test). C: RNA-Seq reads from bioproject PRJNA631793 and PRJNA665066 were analyzed for Pon2 gene expression. The values (rpkm) of the HSC of young mice were set as 1fold. Shown are the mean ± SEM (*** p < 0.001 ** p < 0.01, ns not significant vs HSC; 1-way Anova with Dunnett’s multiple comparisons test). D: RNA-Seq reads from bioproject PRJNA524895, PRJNA528500 and PRJNA635499 and Microarray-Data from GSE76276; were analyzed for Pon2 gene expression. The values (rpkm or normalized intensities) of the young mice were set as 100 %. Shown are the Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 2 mean ± SEM (ns not significant vs. LT-HSC cells form young mice; 1-way Anova with Dunnett’s multiple comparisons test). 4 5 Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 3 A B ns 200 ns *** 150 *** *** *** 100 50 0 PON2 mRNA expression (% of WT/WT) PON2 mRNA WT PON2-/- PON2-/- WT recipient WT PON2-/- WT PON2-/- donor C D E ns ns * ns ns ns ns ns 5 ns ns 6×10 5 ns WBMC) 3×10 WBMC) 8 ns 8 WBMC) * ns 8 ns ns ns ns 5 4×10 2×105 5 2×10 1×105 0 0 0 WT PON2-/- PON2-/- WT -/- -/- -/- -/- recipient recipient WT PON2 PON2 WT recipient WT PON2 PON2 WT -/- -/- donor WT PON2 WT PON2 -/- -/- -/- -/- donor WT PON2 WT PON2 MPPs (abs. cell number per 2.5 10 donor WT PON2 WT PON2 LT-HSCs (abs. cell number per 2.5 10 ST-HSCs (abs. cell number per 2.5 10 ST-HSCs F G ns H ns ns ns ns ns ns ns ** ns 6 ns 5 6 1.5×10 8×10 * ns 1.5×10 ns WBMC) WBMC) WBMC) 8 8 ns 8 ** ns ns 6×105 1.0×106 1.0×106 4×105 5.0×105 5.0×105 2×105 0.0 0 0.0 -/- -/- -/- -/- recipient WT PON2 PON2 WT recipient WT PON2 PON2 WT recipient WT PON2-/- PON2-/- WT -/- -/- -/- -/- MEPs (abs. cell number per 2.5 10 CMPs (abs. cell number per 2.5 10 donor WT PON2 WT PON2 donor WT PON2 WT PON2 GMPs (abs. cell number per 2.5 10 donor WT PON2-/- WT PON2-/- 6 7 8 Figure S2. In young Pon2-/- mice, reciprocal BM transplantation reveals cell intrinsic as 9 well as extrinsic pHenotypes. (A) Experimental scheme for reciprocal transplantation. (B) 10 Verification of engraftment of hematopoietic stem cells and reconstitution of hematopoiesis by 11 donor stem cells in recipient mice using qRT-PCR based analysis of Pon2 mRNA expression 12 in isolated blood cells of transplanted animals (n=8-10). Results are presented as percentage 13 of WT/WT and normalized to Gapd- and Actb-mRNA expression. (C) Percentage of LT-, (D) 14 ST-HSCs, (E) MPPs, (F) CMPs, (G) MEPs and (H) GMPs in WBMCs of BM-chimeras and 15 transplantation controls (n=10-13). Box and whiskers; Whiskers: 10-90 percentile. * p≤0.05, ** 16 p≤0.01, ns not significant; One-way Anova with Tukey's multiple comparisons test. Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 4 A B young aged WT WT PON2-/- PON2-/- counts counts gamma-H2AX FITC-A gamma-H2AX FITC-A 17 18 19 Figure S3. Pon2-/- BMCs show no enhanced amount of DNA double-stand breaks in LSK 20 cells. Overlay of histograms showing the amount of DNA double-strand breaks in WT (green) 21 and Pon2-/- (red) LSK cells, determined by anti-gamma-H2AX staining using BMCs from (A) 22 young or (B) aged animals. One representative of 4 experiments is shown. 23 24 Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 5 25 G0 Colony forming units Colony forming units A G1 LSK B G0 LT-HSC's C D S,M,G2 G1 150 30 S,M,G2 WT ns ns PON2-/- ns ns ns 100 ns ns cells 100 4 ns ns ns 100 ns ns cells 20 4 ns 75 ns ns ns ns ns 75 50 50 10 50 Colonies / 10 total Colonies / 10 Cell cycle phase (%) 25 Cell cycle phase (%) 25 0 0 WT PON2-/- -M -G -GM -GEMM -E 0 0 WT PON2-/- WT PON2-/- F Homing E 50 45 ns 40 35 30 25 20 15 10 % DiI pos. cells 5 0 WT-BM PON2-/--BM 26 27 28 29 30 Figure S4. Bone marrow cells of young Pon2-/- and WT mice show no differences in cell 31 cycle status, colony forming ability and Homing. (A/B) Cell-cycle analysis of LSK (A) and 32 LT-HSCs (B) of young WT and Pon2-/- mice as percentage within each cell-cycle phase (n=6). 33 (C) Colony-forming unit assay (CFU): Total numbers of counted colonies and (D) observed 34 CFU-M (colony-forming unit macrophage), CFU-G (colony-forming unit granulocyte), CFU-GM 35 (colony-forming unit granulocyte/macrophage), CFU-GEMM (colony-forming unit granulocyte/ 36 erythroid/macrophage/megakaryocyte) and CFU-E (colony-forming unit erythroid) colonies 37 from 3x104 WT and Pon2-/- BMC’s, 10-12 days after plating (n=12). (E) Experimental scheme 38 of homing experiment. (F) Percentage of DiI positive WT and Pon2-/- BMCs isolated by flushing 39 tibial and femoral bones of lethally irradiated WT recipient mice 48 hours after transplantation 40 (n=10); ns not significant vs. WT, two tailed unpaired t-test. 41 42 Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 6 43 A LSK-fraction: LT-HSCs: lin-, Sca1+, ckit+, CD150+, CD135- ST-HSCs: lin-, Sca1+, ckit+, CD150-, CD135- MPPs: lin-, Sca1+, ckit+, CD150-, CD135+ B Oligopotent progenitors – myeloid lineage CMPs: lin-, Sca1-, ckit+, CD16/32-, CD34+ GMPs: lin-, Sca1-, ckit+, CD16/32+, CD34+ MEPs: lin-, Sca1-, ckit+, CD16/32-, CD34- C Apoptosis Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 7 D Competitive transplantation Donor Recipient E Cell cycle A - SSC Count Hoechst 33342 Hoechst FSC-A Hoechst 33342 Hoechst 33342 A LSK A - - A - Cy5 - PE ckit lin Alexa 700 lin Alexa CD150 PE FSC-A Sca APC-Cy7-A CD48 PE-Cy7-A Cell cycle LT-HSCs Cell cycle LSK cells Gates Q1 and Q 1-1 represent cells in G1- 67 67 - - phase, Gates Q2 and Q2-1 represent cells Ki Ki in the G2-, S- & M-phases and Gates Q3 and. Q3-1 represent cells Zellen the G0- phase. Hoechst 33342 Hoechst 33342 F Homing DiI-A Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 8 G Total ROS-Level H DNA-damage I Erythrocyte Precursors Figure S5. Gating strategies. Gating strategy for the measurement of (A) HSPC subpopulations within the LSK fraction of BM, (B) Oligopotent progenitors in the BM (C) apoptotic rate of LT- and ST-HSCs, (D) CD45.1 or CD45.2 cells in competitive transplantation experiments, (E) LSK cells and LT-HSCs in different stages of the cell cycle, (F) Dil-positive cells in homing experiments, (G) total ROS-Level of LT-, ST-HSCs and MPP, (H) DNA-damage experiments (I) Erythrocyte Precursor cells. 44 FACSDiva Version 6.1.3 FACSDiva Version 6.1.3 FACSDiva Version 6.1.3 FACSDiva Version 6.1.3 Spiecker et al. The redox enzyme paraoxonase-2 modulates hematopoiesis 9 A B C D E F 45 Figure S6. Representative Histograms sHowing the DCF-DA data of LT- and ST-HSC as 46 wellH2DCF-DA as MPP BM isolated from young WT and Pon2PageH2DCF-DA-/ -2 mice. of 7 BM Printed on: Wed Feb 10, 2016 10:51:25Page CET 3 of 7 Printed on: Wed Feb 10, 2016 10:51:30 CET 47 Total ROS-level in LT- (A/B), ST-HSCs (C/D) and MPPs (E/F) of young (2-3 months) WT H2DCF-DA BM Page 4 of 7 Printed on: Wed Feb 10, 2016 10:51:36 CET 48 (A/C/E) and Pon2-/- (B/D/E) mice stained with cell specific markers (LT-HSCs: Lin-, Sca1+, 49 ckit+, CD135-, CD150+; ST-HSCs: Lin-, Sca1+, ckit+, CD135-, CD150-; MPPs: Lin-, Sca1+, 50 ckit+,H2DCF-DA CD135+, BM CD150-) and H2DCF-DA, analyzedPage 1 ofby 7 FACS (n=12Printed-13). on: Wed Feb 10, 2016 10:51:20 CET 51 52 Spiecker et al.
Load more

Recommended publications
  • Mir-338-3P Functions As a Tumor Suppressor in Gastric Cancer by Targeting PTP1B
    Sun et al. Cell Death and Disease DOI 10.1038/s41419-018-0611-0 Cell Death & Disease ARTICLE Open Access miR-338-3p functions as a tumor suppressor in gastric cancer by targeting PTP1B Feng Sun1, Mengchao Yu2,JingYu2, Zhijian Liu1,XinyanZhou2,YanqingLiu2, Xiaolong Ge3,HaidongGao2, Mei Li4, Xiaohong Jiang2,SongLiu1,XiChen2 and Wenxian Guan 1 Abstract Gastric cancer (GC) is one of the most common malignant tumors and peritoneal metastasis is the primary cause for advanced GC’s mortality. Protein-tyrosine phosphatase 1B (PTP1B) functions as an oncogene and involves in carcinogenesis and cancer dissemination. However, the function and regulation of PTP1B in GC remain poorly understood. In this study, we found that PTP1B was upregulated in GC tissues and overexpression of PTP1B in vitro promoted cell migration and prevented apoptosis. Then, we predicted that PTP1B was a target of miR-338-3p and we revealed an inverse correlation between miR-338-3p levels and PTP1B protein levels in GC tissues. Next, we verified that PTP1B was inhibited by miR-338-3p via direct targeting to its 3′-untranslated regions. Moreover, overexpression of miR-338-3p in vitro attenuated GC cell migration and promoted apoptosis, and these effects could be partially reversed by reintroduction of PTP1B. Finally, we established an orthotopic xenograft model and a peritoneal dissemination model of GC to demonstrate that miR-338-3p restrained tumor growth and dissemination in vivo by targeting PTP1B. Taken together, our results highlight that PTP1B is an oncogene and is negatively regulated by miR- 1234567890():,; 1234567890():,; 338-3p in GC, which may provide new insights into novel molecular therapeutic targets for GC.
    [Show full text]
  • Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) Through Multikinase Inhibition Jessica D
    Published OnlineFirst February 9, 2018; DOI: 10.1158/1078-0432.CCR-17-1928 Cancer Therapy: Preclinical Clinical Cancer Research Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition Jessica D. Lang1,William P.D. Hendricks1, Krystal A. Orlando2, Hongwei Yin1, Jeffrey Kiefer1, Pilar Ramos1, Ritin Sharma3, Patrick Pirrotte3, Elizabeth A. Raupach1,3, Chris Sereduk1, Nanyun Tang1, Winnie S. Liang1, Megan Washington1, Salvatore J. Facista1, Victoria L. Zismann1, Emily M. Cousins4, Michael B. Major4, Yemin Wang5, Anthony N. Karnezis5, Aleksandar Sekulic1,6, Ralf Hass7, Barbara C. Vanderhyden8, Praveen Nair9, Bernard E. Weissman2, David G. Huntsman5,10, and Jeffrey M. Trent1 Abstract Purpose: Small cell carcinoma of the ovary, hypercalcemic type three SWI/SNF wild-type ovarian cancer cell lines. We further (SCCOHT) is a rare, aggressive ovarian cancer in young women identified ponatinib as the most effective clinically approved that is universally driven by loss of the SWI/SNF ATPase subunits RTK inhibitor. Reexpression of SMARCA4 was shown to confer SMARCA4 and SMARCA2. A great need exists for effective targeted a 1.7-fold increase in resistance to ponatinib. Subsequent therapies for SCCOHT. proteomic assessment of ponatinib target modulation in Experimental Design: To identify underlying therapeutic vul- SCCOHT cell models confirmed inhibition of nine known nerabilities in SCCOHT, we conducted high-throughput siRNA ponatinib target kinases alongside 77 noncanonical ponatinib and drug screens. Complementary proteomics approaches pro- targets in SCCOHT. Finally, ponatinib delayed tumor dou- filed kinases inhibited by ponatinib. Ponatinib was tested for bling time 4-fold in SCCOHT-1 xenografts while reducing efficacy in two patient-derived xenograft (PDX) models and one final tumor volumes in SCCOHT PDX models by 58.6% and cell-line xenograft model of SCCOHT.
    [Show full text]
  • Hyperactive and Impulsive Behaviors of LMTK1 Knockout Mice
    www.nature.com/scientificreports OPEN Hyperactive and impulsive behaviors of LMTK1 knockout mice Miyuki Takahashi1,7, Arika Sugiyama1, Ran Wei1, Shizuka Kobayashi2, Kimiko Fukuda3, Hironori Nishino1, Roka Takahashi1, Koji Tsutsumi1,8, Ichiro Kita4, Kanae Ando1, Toshiya Manabe2, Hiroyuki Kamiguchi5, Mineko Tomomura6 & Shin‑ichi Hisanaga1* Lemur tail kinase 1 (LMTK1), previously called Apoptosis‑Associated Tyrosine Kinase (AATYK), remains an uncharacterized Ser/Thr protein kinase that is predominantly expressed in the brain. It is recently reported that LMTK1A, an isoform of LMTK1, binds to recycling endosomes through its palmitoylation and regulates endosomal trafcking by suppressing the activity of Rab11 small GTPase. In neurons, knockdown or knockout of LMTK1 results in longer axons, greater branching of dendrites and increased number of spines, suggesting that LMTK1 plays a role in neuronal circuit formation. However, its in vivo function remained to be investigated. Here, we examined the brain structures and behaviors of LMTK1 knockout (KO) mice. LMTK1 was expressed in most neurons throughout the brain. The overall brain structure appeared to be normal in LMTK1 KO mice, but the numbers of synapses were increased. LMTK1 KO mice had a slight impairment in memory formation and exhibited distinct psychiatric behaviors such as hyperactivity, impulsiveness and high motor coordination without social interaction defcits. Some of these abnormal behaviors represent core features of attention defcit hyperactive disorder (ADHD), suggesting the possible involvement of LMTK1 in the pathogenesis of ADHD. Abbreviations AATYK1 Apoptosis-Associated Tyrosine Kinase ADHD Attention defcit hyperactive disorder Cx Cerebral cortex Cb Cerebellum CS Conditioned stimulus ISH In situ hybridization KO Knockout LMTK Lemur tail kinase PPF Paired-pulse facilitation US Unconditioned stimulus WT Wildtype Neuronal circuit wiring is the structural and functional basis of higher brain activities such as recognition and behaviors.
    [Show full text]
  • 1714 Gene Comprehensive Cancer Panel Enriched for Clinically Actionable Genes with Additional Biologically Relevant Genes 400-500X Average Coverage on Tumor
    xO GENE PANEL 1714 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes 400-500x average coverage on tumor Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11 IL6R KAT5 ACVR2A
    [Show full text]
  • The Apoptosis Associated Tyrosine Kinase Gene Is Frequently Hypermethylated in Human Cancer and Is Regulated by Epigenetic Mechanisms
    www.impactjournals.com/Genes&Cancer Genes & Cancer, Vol. 5 (9-10), September 2014 The apoptosis associated tyrosine kinase gene is frequently hypermethylated in human cancer and is regulated by epigenetic mechanisms Tanja Haag1, Christina E. Herkt1, Sara K. Walesch1, Antje M. Richter1 and Reinhard H. Dammann1 1 Institute for Genetics; Justus-Liebig-University; Universities of Giessen and Marburg Lung Center, Member of the German Center for Lung Research; Giessen, Germany Correspondence to: Reinhard H. Dammann, email: [email protected] Keywords: AATK/ epigenetic regulation / DNA methylation/ human cancer/ tumor suppressor/ CTCF Received: July 30, 2014 Accepted: August 18, 2014 Published: August 19, 2014 This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT: Epigenetic gene inactivation through promoter hypermethylation is an important aberration involved in the silencing of tumor-associated genes in cancer. Here we identified the apoptosis associated tyrosine kinase (AATK) as an epigenetically downregulated tumor related gene. We analyzed the epigenetic regulation of AATK in several human cancer cell lines and normal tissues by methylation and expression analysis. Hypermethylation of AATK was also analyzed in 25 primary lung tumors, 30 breast cancers and 24 matching breast tissues. In normal tissues the AATK CpG island promoter was unmethylated and AATK was expressed. Hypermethylation of AATK occurred frequently in 13 out of 14 (93%) human cancer cell lines. Methylation was reversed by 5-aza-2’-deoxycytidine treatment leading to re-expression of AATK in cancer cell lines.
    [Show full text]
  • Circptk2 Suppresses the Progression of Gastric Cancer by Targeting Mir-196A-3P/AATK Axis
    CircPTK2 Suppresses the Progression of Gastric Cancer by Targeting miR-196a-3p/AATK Axis Ling Gao The First Aliated Hospital of Soochow University Tingting Xia The First Aliated Hospital of Soochow University Mingde Qin Soochow University Xiaofeng Xue The First Aliated Hospital of Soochow University Linhua Jiang The First Aliated Hospital of Soochow University Xinguo Zhu ( [email protected] ) The First Aliated Hospital of Soochow University https://orcid.org/0000-0001-9686-6797 Primary research Keywords: Gastric cancer, circPTK2, miR-196a-3p, AATK Posted Date: June 8th, 2021 DOI: https://doi.org/10.21203/rs.3.rs-569952/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/20 Abstract Background Gastric cancer is a type of malignant tumor with high morbidity and mortality. It has been shown that circular RNAs (circRNAs) exert critical functions in gastric cancer progression via working as microRNA (miRNA) sponges to regulate gene expression. However, the role and potential molecular mechanism of circRNAs in gastric cancer remain largely unknown. Methods CircPTK2 (hsa_circ_0005273) was identied by bioinformatics analysis and validated by RT-qPCR assay. Bioinformatics prediction, dual-luciferase reporter and RNA pull down assays were used to determine the interaction between circPTK2, miR-196a-3p, AATK. Results The level of circPTK2 was markedly downregulated in gastric cancer tissues. Upregulation of circPTK2 suppressed the proliferation, migration and invasion of gastric cancer cells, while downregulation of circPTK2 exhibited opposite effects. Mechanically, circPTK2 could competitively bind to miR-196a-3p and prevent miR-196a-3p to reduce the expression of AATK.
    [Show full text]
  • Deficiency of Antioxidative Paraoxonase 2 (Pon2) Leads to Increased Number of Phenotypic LT-Hscs and Disturbed Erythropoiesis
    Hindawi Oxidative Medicine and Cellular Longevity Volume 2021, Article ID 3917028, 18 pages https://doi.org/10.1155/2021/3917028 Research Article Deficiency of Antioxidative Paraoxonase 2 (Pon2) Leads to Increased Number of Phenotypic LT-HSCs and Disturbed Erythropoiesis Lisa Spiecker ,1 Ines Witte ,1 Julia Mehlig ,1 Viral Shah ,2,3 Markus Meyerhöfer,2,3 Patricia S. Haehnel ,2,3 Victoria Petermann ,1 Andrea Schüler,2 Piyush More ,1 Nina Cabezas-Wallscheid ,4 Sven Horke ,1 Andrea Pautz ,1 Andreas Daiber ,5 Daniel Sasca ,2,3 Thomas Kindler ,2,3 and Hartmut Kleinert 1 1Department of Pharmacology, Johannes Gutenberg University Medical Center, Mainz, Germany 2Department of Hematology, Medical Oncology and Pneumology, University Medical Center, Mainz, Germany 3University Cancer Center of Mainz, Germany 4Max Planck Institute of Immunobiology and Epigenetics, 79108 Freiburg, Germany 5Department of Cardiology, Cardiology I, Johannes Gutenberg University Medical Center Mainz, Germany Correspondence should be addressed to Daniel Sasca; [email protected], Thomas Kindler; [email protected], and Hartmut Kleinert; [email protected] Received 29 June 2020; Revised 26 April 2021; Accepted 27 May 2021; Published 25 June 2021 Academic Editor: Liren Qian Copyright © 2021 Lisa Spiecker et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The publication of this article was funded by Max Planck. Background. Long-term hematopoietic stem cells (LT-HSCs) reside in bone marrow niches with tightly controlled reactive oxygen species (ROS) levels. ROS increase results into LT-HSC differentiation and stem cell exhaustion.
    [Show full text]
  • Article (Published Version)
    Article Kinases and Cancer CICENAS, Jonas, et al. Abstract Protein kinases are a large family of enzymes catalyzing protein phosphorylation. The human genome contains 518 protein kinase genes, 478 of which belong to the classical protein kinase family and 40 are atypical protein kinases [...]. Reference CICENAS, Jonas, et al. Kinases and Cancer. Cancers, 2018, vol. 10, no. 3 DOI : 10.3390/cancers10030063 PMID : 29494549 Available at: http://archive-ouverte.unige.ch/unige:105089 Disclaimer: layout of this document may differ from the published version. 1 / 1 cancers Editorial Kinases and Cancer Jonas Cicenas 1,2,3,* ID , Egle Zalyte 2, Amos Bairoch 4,5 ID and Pascale Gaudet 4,* 1 Department of Microbiology, Immunology and Genetics, Max F. Perutz Laboratories, University of Vienna, 1030 Vienna, Austria 2 Proteomics Center, Institute of Biochemistry, Vilnius University Life Sciences Center, Sauletekio al. 7, LT-10257 Vilnius, Lithuania; [email protected] 3 MAP Kinase Resource, Bioinformatics, Melchiorstrasse 9, 3027 Bern, Switzerland 4 CALIPHO Group, SIB Swiss Institute of Bioinformatics, 1 rue Michel-Servet, CH-1211 Geneva 4, Switzerland; [email protected] 5 Faculty of Medicine; University of Geneva; 1 rue Michel-Servet, CH-1211 Geneva 4, Switzerland * Correspondence: [email protected] (J.C.); [email protected] (P.G.); Tel.: +43-664-5875822 (J.C.) Received: 27 February 2018; Accepted: 28 February 2018; Published: 1 March 2018 Protein kinases are a large family of enzymes catalyzing protein phosphorylation. The human genome contains 518 protein kinase genes, 478 of which belong to the classical protein kinase family and 40 are atypical protein kinases.
    [Show full text]
  • Induced Multipotent Hematopoietic Progenitor Cell Self
    CONTRASTING ROLES OF C/EBPα AND NOTCH IN IONIZING RADIAITON- INDUCED MULTIPOTENT HEMATOPOIETIC PROGENITOR CELL SELF- RENEWAL DEFECTS by COURTNEY JO FLEENOR B.S., University of Iowa, 2008 A thesis submitted to the Faculty of the Graduate School of the University of Colorado in partial fulfillment of the requirements for the degree of Doctor of Philosophy Immunology Program 2015 This thesis for the Doctor of Philosophy degree by Courtney Jo Fleenor has been approved for the Immunology Program by Philippa Marrack, Chair John Cambier Heide Ford James Hagman Jill Slansky James DeGregori, Advisor Date 12/31/14 ii Fleenor, Courtney Jo (Ph.D., Immunology) Contrasting Roles of C/EBPα and Notch in Ionizing Radiation-Induced Multipotent Hematopoietic Progenitor Cell Self-Renewal Thesis directed by Professor James V. DeGregori. ABSTRACT Ionizing radiation (IR) is associated with persistent panhematopoietic defects and increased risk of carcinogenesis, although the mechanism underlying these relationship remains largely unknown. The increasing exposure of humans to man-made sources of IR, primarily through medical procedures, exemplifies a critical need to understand how IR elicits adverse health affects. Mice exposed to IR develop a disease similar to human T-cell acute lymphoblastic lymphoma, of which over 50% are associated with activating Notch mutations. Furthermore, our lab has previously shown that the activated intracellular Notch mutant, ICN1, is selected for and promotes lymphomagenesis within previously irradiated mice. As pan-hematopoietic defects persist long after the exposure event, I hypothesized that IR reduces hematopoietic stem cell (HSC) function, increasing selective pressure for activating Notch mutations that repair or circumvent the IR-mediated defect.
    [Show full text]
  • Molecular Analysis of Insulin Action Using High Throughput Genetic Screens
    Molecular analysis of insulin action using high throughput genetic screens Poh Sim Khoo Thesis submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Garvan Institute of Medical Research University of New South Wales 31st March 2011 PLEASE TYPE THE UNIVERSITY OF NEW SOUTH WALES Thesis/Dissertation Sheet Surname or Family name: Khoo First name: Poh Sim Other name/s: Abbreviation for degree as given in the University calendar: PhD School: St Vincent's Cllinical School Faculty:Medicine Title: Molecular analysis of insulin action using high throughput genetic screens Abstract 350 words maximum: (PLEASE TYPE) The insulin-stimulated uptake of glucose by muscle and adipose is vital for the maintenance of glucose homeostasis in the body. This uptake primarily occurs through the action of the insulin-regulatable glucose transporter GLUT4, which is rapidly translocated to the plasma membrane in response to the insulin signal. However, in the insulin resistant state, insulin is unable to effect a normal biological response in its target tissues, characterized by decreased glucose uptake as a result of defects in insulin signaling and attenuated GLUT4 translocation. Elucidating the molecular causes underlying insulin resistance is important for the development of therapeutics for this disease. Identifying the components involved in the propagation or regulation of insulin signaling is an important step in understanding insulin resistance. To date, the upstream components of the signaling pathway are well established, demonstrating the importance of the insulin receptor, IRS proteins and PI3K/Akt signaling axis in this process. As a result much work has focused on defects at the point of IRS in the development of insulin resistance.
    [Show full text]
  • Xo PANEL DNA GENE LIST
    xO PANEL DNA GENE LIST ~1700 gene comprehensive cancer panel enriched for clinically actionable genes with additional biologically relevant genes (at 400 -500x average coverage on tumor) Genes A-C Genes D-F Genes G-I Genes J-L AATK ATAD2B BTG1 CDH7 CREM DACH1 EPHA1 FES G6PC3 HGF IL18RAP JADE1 LMO1 ABCA1 ATF1 BTG2 CDK1 CRHR1 DACH2 EPHA2 FEV G6PD HIF1A IL1R1 JAK1 LMO2 ABCB1 ATM BTG3 CDK10 CRK DAXX EPHA3 FGF1 GAB1 HIF1AN IL1R2 JAK2 LMO7 ABCB11 ATR BTK CDK11A CRKL DBH EPHA4 FGF10 GAB2 HIST1H1E IL1RAP JAK3 LMTK2 ABCB4 ATRX BTRC CDK11B CRLF2 DCC EPHA5 FGF11 GABPA HIST1H3B IL20RA JARID2 LMTK3 ABCC1 AURKA BUB1 CDK12 CRTC1 DCUN1D1 EPHA6 FGF12 GALNT12 HIST1H4E IL20RB JAZF1 LPHN2 ABCC2 AURKB BUB1B CDK13 CRTC2 DCUN1D2 EPHA7 FGF13 GATA1 HLA-A IL21R JMJD1C LPHN3 ABCG1 AURKC BUB3 CDK14 CRTC3 DDB2 EPHA8 FGF14 GATA2 HLA-B IL22RA1 JMJD4 LPP ABCG2 AXIN1 C11orf30 CDK15 CSF1 DDIT3 EPHB1 FGF16 GATA3 HLF IL22RA2 JMJD6 LRP1B ABI1 AXIN2 CACNA1C CDK16 CSF1R DDR1 EPHB2 FGF17 GATA5 HLTF IL23R JMJD7 LRP5 ABL1 AXL CACNA1S CDK17 CSF2RA DDR2 EPHB3 FGF18 GATA6 HMGA1 IL2RA JMJD8 LRP6 ABL2 B2M CACNB2 CDK18 CSF2RB DDX3X EPHB4 FGF19 GDNF HMGA2 IL2RB JUN LRRK2 ACE BABAM1 CADM2 CDK19 CSF3R DDX5 EPHB6 FGF2 GFI1 HMGCR IL2RG JUNB LSM1 ACSL6 BACH1 CALR CDK2 CSK DDX6 EPOR FGF20 GFI1B HNF1A IL3 JUND LTK ACTA2 BACH2 CAMTA1 CDK20 CSNK1D DEK ERBB2 FGF21 GFRA4 HNF1B IL3RA JUP LYL1 ACTC1 BAG4 CAPRIN2 CDK3 CSNK1E DHFR ERBB3 FGF22 GGCX HNRNPA3 IL4R KAT2A LYN ACVR1 BAI3 CARD10 CDK4 CTCF DHH ERBB4 FGF23 GHR HOXA10 IL5RA KAT2B LZTR1 ACVR1B BAP1 CARD11 CDK5 CTCFL DIAPH1 ERCC1 FGF3 GID4 HOXA11
    [Show full text]
  • Protein Kinase
    Flexi® ORF Clone www.promega.co.jp/flexiclone/ Protein Kinase 355個 （2012/4/1 現在） 遺伝子シンボル 説明 FXC_PID 価格 FHC_PID 価格 AAK1 AP2 associated kinase 1 FXC00722 ¥40,000 FHC00722 ¥50,000 AATK apoptosis-associated tyrosine kinase FXC04004 ¥40,000 FHC04004M ¥60,000 ABL1 c-abl oncogene 1, receptor tyrosine kinase FXC01406 ¥40,000 FHC01406 ¥50,000 ACTR2 ARP2 actin-related protein 2 homolog (yeast) FXC02146 ¥40,000 FHC02146 ¥50,000 Activin receptor type-1 Precursor (EC 2.7.11.30)(Activin receptor type I)(ACTR-I)(Serine/threonine-protein kinase ACVR1 FXC03971 ¥40,000 FHC03971 ¥50,000 receptor R1)(SKR1)(Activin receptor-like kinase 2)(ALK- 2)(TGF-B superfamily receptor type I)(TSR-I) ACVR1B activin A receptor, type IB FXC01408 ¥40,000 FHC01408 ¥50,000 ACVR1C activin A receptor, type IC FXC09109M ¥50,000 FHC09109 ¥50,000 ACVRL1 activin A receptor type II-like 1, transcript variant 1 FXC28135M ¥50,000 FHC28135 ¥50,000 ADRBK1 adrenergic, beta, receptor kinase 1 FXC09648M ¥50,000 FHC09648 ¥50,000 ADRBK2 adrenergic, beta, receptor kinase 2 FXC27231M ¥50,000 FHC27231 ¥50,000 AKT1 v-akt murine thymoma viral oncogene homolog 1 FXC02215 ¥40,000 FHC02215 ¥50,000 AKT2 v-akt murine thymoma viral oncogene homolog 2 FXC26633 ¥40,000 FHC26633 ¥50,000 v-akt murine thymoma viral oncogene homolog 3 (protein AKT3 FXC02812 ¥40,000 FHC02812 ¥50,000 kinase B, gamma) ALK anaplastic lymphoma receptor tyrosine kinase FXC00337 ¥40,000 FHC00337 ¥50,000 A-Raf proto-oncogene serine/threonine-protein kinase (EC ARAF FXC08066 ¥40,000 FHC08066 ¥50,000 2.7.11.1)(A-raf-1)(Proto-oncogene
    [Show full text]